SRPT250502C51000
- 10.05
- 0.000.00%
Sarepta Therapeutics Newsroom
Earnings Preview: SRPT to Report Financial Results Post-market on May 06
Piper Sandler Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $110
TD Cowen Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $203
New Analyst Forecast: $SRPT Given $110.0 Price Target
Press Release: Sarepta Therapeutics to Announce First Quarter 2025 Financial Results
Piper Sandler Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Cuts Target Price to $110
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results
Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Long-Term Stock According to Analysts?
Netflix To Rally More Than 55%? Here Are 10 Top Analyst Forecasts For Monday
Sarepta Therapeutics Is Maintained at Overweight by Piper Sandler
Analysts' Top Healthcare Picks: Sarepta Therapeutics (SRPT), Evolent Health (EVH)
Analysts Conflicted on These Healthcare Names: Apellis Pharmaceuticals (APLS), Skye Bioscience (SKYE) and Sarepta Therapeutics (SRPT)
BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $157
Express News | Sarepta Therapeutics Inc : Piper Sandler Cuts Target Price to $110 From $182
Sarepta Price Target Lowered to $157 From $179 at BofA
10 Health Care Stocks Whale Activity In Today's Session
BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Announces Target Price $157
Unusual Options Activity: PDD, SRPT and Others Attract Market Bets, PDD V/OI Ratio Reaches 130.1
BofA Adjusts Price Target on Sarepta Therapeutics to $157 From $179, Keeps Buy Rating
Sarepta Therapeutics (SRPT) Receives a Buy From Bank of America Securities